Stratasys Origin One and its Programmable Photopolymerization P3™ technology are an ideal solution for rapid development and production of medical components. Materials from Stratasys’ ecosystem material partner network include medical-grade materials from multiple global chemical companies that can be brought quickly into the Stratasys ecosystem, validated and put into production. In the early stages of the product’s development, Origin surveyed no less than 20 materials, many of which had the ability to pass the biocompatibility requirements, before deciding on LOCTITE MED412 for its unique stiffness and flexibility.
The company was able to ramp up from passing clinical trials to mass production in a matter of days, a far cry from traditional injection molding tooling lead times. Plus, it was possible to easily increase capacity by dedicating additional 3D printers to production. During the same time period, Origin’s customers also produced thousands of units of PPE, respirator components and ventilator components, demonstrating the ability of the technology to be used for various other applications in short supply.
The Stratasys Origin One’s printing technology and access to high-performance materials enable fast iterations and accelerated concept development. This makes it an ideal choice for the rapid development and production of biocompatible components, and it’s what enabled the company to swiftly lend a helping hand during an unprecedented global pandemic.